Distinct Sets of Genetic Alterations in Melanoma
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Exposure to ultraviolet light is a major causative factor in melanoma, although the relationship between risk and exposure is complex. We hypothesized that the clinical heterogeneity is explained by genetically distinct types of melanoma with different susceptibility to ultraviolet light. METHODS: We compared genome-wide alterations in the number of copies of DNA and mutational status of BRAF and N-RAS in 126 melanomas from four groups in which the degree of exposure to ultraviolet light differs: 30 melanomas from skin with chronic sun-induced damage and 40 melanomas from skin without such damage; 36 melanomas from palms, soles, and subungual (acral) sites; and 20 mucosal melanomas. RESULTS: We found significant differences in the frequencies of regional changes in the number of copies of DNA and mutation frequencies in BRAF among the four groups of melanomas. Samples could be correctly classified into the four groups with 70 percent accuracy on the basis of the changes in the number of copies of genomic DNA. In two-way comparisons, melanomas arising on skin with signs of chronic sun-induced damage and skin without such signs could be correctly classified with 84 percent accuracy. Acral melanoma could be distinguished from mucosal melanoma with 89 percent accuracy. Eighty-one percent of melanomas on skin without chronic sun-induced damage had mutations in BRAF or N-RAS; the majority of melanomas in the other groups had mutations in neither gene. Melanomas with wild-type BRAF or N-RAS frequently had increases in the number of copies of the genes for cyclin-dependent kinase 4 (CDK4) and cyclin D1 (CCND1), downstream components of the RAS-BRAF pathway. CONCLUSIONS: The genetic alterations identified in melanomas at different sites and with different levels of sun exposure indicate that there are distinct genetic pathways in the development of melanoma and implicate CDK4 and CCND1 as independent oncogenes in melanomas without mutations in BRAF or N-RAS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While these mutations are not UV-signature mutations20, they are more common in sun-exposed skin20–23.”
From Mechanisms and prevention of UV‐induced melanoma (2018) · cites this paper as [20]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
R: A Language for Data Analysis and Graphics
Ihaka, R., & Gentleman, R. (1996) · Journal of Computational and Graphical Statistics · doi:10.1080/10618600.1996.10474713 · Cited by 11,220
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650
Comparison of Discrimination Methods for the Classification of Tumors Using Gene Expression Data
Dudoit, S., Fridlyand, J., & Speed, T. P. (2002) · Journal of the American Statistical Association · doi:10.1198/016214502753479248 · Cited by 2,672
Self-citationPinkel, D., Segraves, R., Sudar, D., Clark, S., Poole, I., Kowbel, D., Collins, C., Kuo, W.-L., Chen, C., Zhai, Y., et al. (1998) · Nature Genetics · doi:10.1038/2524 · Cited by 2,240
Self-citationThe histogenesis and biologic behavior of primary human malignant melanomas of the skin.
Clark, W. H., From, L., Bernardino, E. A., & Mihm, M. C. (1969) · PubMed · Cited by 2,112
High frequency of BRAF mutations in nevi
Pollock, P. M., Harper, U. L., Hansen, K. S., Yudt, L. M., Stark, M., Robbins, C. M., Moses, T. Y., Hostetter, G., Wagner, U., Kakareka, J., et al. (2003) · Nature Genetics · doi:10.1038/ng1054 · Cited by 1,730
Resampling-Based Multiple Testing: Examples and Methods for p-Value Adjustment.
Martin, M. A., Westfall, P. H., & Young, S. S. (1994) · Biometrics · doi:10.2307/2533464 · Cited by 1,699
Role of the INK4a Locus in Tumor Suppression and Cell Mortality
Serrano, M., Lee, H.-W., Chin, L., Cordon-Cardo, C., Beach, D., & DePinho, R. A. (1996) · Cell · doi:10.1016/s0092-8674(00)81079-x · Cited by 1,585
LOWESS: A Program for Smoothing Scatterplots by Robust Locally Weighted Regression
Cleveland, W. S. (1981) · The American Statistician · doi:10.2307/2683591 · Cited by 1,150
Cited by
Items 501–600 of 1,006
PI3-Kinase Subunits Are Infrequent Somatic Targets in Melanoma
Curtin, J. A., Stark, M. S., Pinkel, D., Hayward, N. K., & Bastian, B. C. (2006) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700311 · Cited by 82
Self-citationWolchok, J. D. (2012) · Annals of Oncology · doi:10.1093/annonc/mds258 · Cited by 81
How many diseases is triple negative breast cancer: the protagonism of the immune microenvironment
Saraiva, D. P., Cabral, M. G., Jacinto, A., & Braga, S. A. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000208 · Cited by 82
Mucosal Melanoma: Epidemiology, Clinical Features, and Treatment
Sergi, M. C., Filoni, E., Triggiano, G., Cazzato, G., Internò, V., Porta, C., & Tucci, M. (2023) · Current Oncology Reports · doi:10.1007/s11912-023-01453-x · Cited by 81
Melanoma of the dog and cat: consensus and guidelines
Polton, G. A., Borrego, J. F., Clemente-Vicario, F., Clifford, C. A., Jagielski, D., Kessler, M., Kobayashi, T., Lanore, D., QUEIROGA, F. L., Rowe, A. T., et al. (2024) · Frontiers in Veterinary Science · doi:10.3389/fvets.2024.1359426 · Cited by 81
Fluorescence in situ hybridization as a tool for microstaging in malignant melanoma
Newman, M. D., Lertsburapa, T., Mirzabeigi, M., Mafee, M., Guitart, J., & Gerami, P. (2009) · Modern Pathology · doi:10.1038/modpathol.2009.72 · Cited by 81
Targeting NADPH oxidases for the treatment of cancer and inflammation
Bonner, M. Y., & Arbiser, J. L. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1017-2 · Cited by 81
Distinction of conjunctival melanocytic nevi from melanomas by fluorescence in situ hybridization
BUSAM, K. J., Fang, Y., Jhanwar, S. C., Pulitzer, M. P., Marr, B. P., & Abramson, D. H. (2009) · Journal of Cutaneous Pathology · doi:10.1111/j.1600-0560.2009.01488.x · Cited by 81
Self-citationBustos, B. D. U., Estal, R. M., Pérez-Simó, G., Jiménez, I. D. J., Muñoz, B. E., Serna, M. R., de Miquel, V. A., Ros, M. L., Sánchez, R. B., Nagore, E., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-00606-w · Cited by 81
Takata, M., Lin, J., Takayanagi, S., Suzuki, T., Ansai, S., Kimura, T., Cerroni, L., & Saida, T. (2007) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2007.07924.x · Cited by 81
Targeting the PD-1 pathway: a promising future for the treatment of melanoma
Mamalis, A., Garcha, M., & Jagdeo, J. R. (2014) · Archives of Dermatological Research · doi:10.1007/s00403-014-1457-7 · Cited by 80
von Euw, E., Atefi, M. S., Attar, N., Chu, C., Zachariah, S., Burgess, B. L., Mok, S., Ng, C., Wong, D. J. L., Chmielowski, B., et al. (2012) · Molecular Cancer · doi:10.1186/1476-4598-11-22 · Cited by 81
micro RNA ‐21 is upregulated in malignant melanoma and influences apoptosis of melanocytic cells
Satzger, I., Mattern, A., Küttler, U., Weinspach, D., Niebuhr, M., Kapp, A., & Gutzmer, R. (2012) · Experimental Dermatology · doi:10.1111/j.1600-0625.2012.01510.x · Cited by 81
Association of galectin-3 expression with melanoma progression and prognosis
Brown, E. R., Doig, T. N., Anderson, N., Brenn, T., Doherty, V. R., Xu, Y., Bartlett, J. M. S., Smyth, J. F., & Melton, D. W. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.09.003 · Cited by 81
Diagnosis and Management of Acral Lentiginous Melanoma
Nakamura, Y., & Fujisawa, Y. (2018) · Current Treatment Options in Oncology · doi:10.1007/s11864-018-0560-y · Cited by 82
Genetics and epigenetics of cutaneous malignant melanoma: A concert out of tune
van den Hurk, K., Niessen, H. E. C., Veeck, J., van den Oord, J. J., Steensel, M. A. M. V., Hausen, A. Z., van Engeland, M., & Winnepenninckx, V. J. L. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.03.011 · Cited by 81
CDK4/6 Inhibitors in Melanoma: A Comprehensive Review
Garutti, M., Targato, G., Buriolla, S., Palmero, L., Minisini, A. M., & Puglisi, F. (2021) · Cells · doi:10.3390/cells10061334 · Cited by 80
Rose, A. E., Poliseno, L., Wang, J., Clark, M., Pearlman, A. W., Wang, G., de Miera, E. C. V. Y. S., Medicherla, R. C., Christos, P. J., Shapiro, R. L., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2958 · Cited by 79
Friedman, R. J., Farber, M. J., Warycha, M. A., Papathasis, N., Miller, M. K., & Heilman, E. R. (2008) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2008.09.008 · Cited by 79
Epigenetic deregulation of TCF21 inhibits metastasis suppressor KISS1 in metastatic melanoma
Arab, K., Smith, L. T., Gast, A., Weichenhan, D., Huang, P.-H., Claus, R., Hielscher, T., Espinosa, A. V., Ringel, M. D., Morris, Q., et al. (2011) · Carcinogenesis · doi:10.1093/carcin/bgr138 · Cited by 79
Yadav, D. K., Adhikari, M., Kumar, S., Ghimire, B., Han, I., Kim, M., & Choi, E. H. (2020) · Scientific Reports · doi:10.1038/s41598-020-60356-0 · Cited by 79
Novel Role for RGS1 in Melanoma Progression
Rangel, J., Nosrati, M., Leong, S. P. L., Haqq, C., Miller, J. R., Sagebiel, R. W., & Kashani–Sabet, M. (2008) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31816fd53c · Cited by 79
Nagasundaram, N., Zhu, H., Liu, J., Vasudevan, K., Doss, C. G. P., Chakraborty, C., & Chen, L. (2015) · PLoS ONE · doi:10.1371/journal.pone.0133969 · Cited by 78
Takata, M., Murata, H., & Saida, T. (2009) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2009.00645.x · Cited by 79
Joseph, R. W., Swaika, A., & Crozier, J. A. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s31143 · Cited by 80
BRAF Mutations and KIT Aberrations and Their Clinicopathological Correlation in 202 Korean Melanomas
Jin, S. A., Chun, S. M., Choi, Y. D., Kweon, S., Jung, S. T., Shim, H. J., & Yun, S. J. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.338 · Cited by 78
Unusual variants of malignant melanoma
Barnhill, R. L., & Gupta, K. (2009) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2008.09.015 · Cited by 78
Zimmer, L., Eigentler, T. K., Kiecker, F., Simon, J., Utikal, J., Mohr, P., Berking, C., Kämpgen, E., Dippel, E., Stadler, R., et al. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0716-5 · Cited by 74
Blokx, W. A. M., van Dijk, M. C. R. F., & Ruiter, D. J. (2009) · Histopathology · doi:10.1111/j.1365-2559.2009.03452.x · Cited by 78
Nras in melanoma: Targeting the undruggable target
Mandalà, M., Merelli, B., & Massi, D. (2014) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2014.05.005 · Cited by 79
The relative contributions of the p53 and pRb pathways in oncogene-induced melanocyte senescence
Haferkamp, S., Tran, S. L., Becker, T. M., Scurr, L. L., Kefford, R. F., & Rizos, H. (2009) · Aging · doi:10.18632/aging.100051 · Cited by 77
Gene signature of the metastatic potential of cutaneous melanoma: too much for too little?
Tímár, J., Győrffy, B., & Rásó, E. (2010) · Clinical & Experimental Metastasis · doi:10.1007/s10585-010-9307-2 · Cited by 77
Falch, C., Stojadinovic, A., Hann-von-Weyhern, C., Protić, M., Nissan, A., Faries, M. B., Däumer, M., Bilchik, A. J., Itzhak, A., & Brücher, B. L. D. M. (2013) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2013.02.031 · Cited by 77
Nielsen, K., Måsbäck, A., Olsson, H. L., & Ingvar, C. (2011) · International Journal of Cancer · doi:10.1002/ijc.26408 · Cited by 77
Somatic p16INK4a loss accelerates melanomagenesis
Monahan, K. B., Rozenberg, G. I., Krishnamurthy, J., Johnson, S. M., Liu, W., Bradford, M. K., Horner, J., DePinho, R. A., & Sharpless, N. E. (2010) · Oncogene · doi:10.1038/onc.2010.314 · Cited by 72
Melanoma therapeutics: a literature review
Dhanyamraju, P. K., & Patel, T. (2022) · Journal of Biomedical Research · doi:10.7555/jbr.36.20210163 · Cited by 76
Current State of Melanoma Therapy and Next Steps: Battling Therapeutic Resistance
Fateeva, A., Eddy, K., & Chen, S. (2024) · Cancers · doi:10.3390/cancers16081571 · Cited by 80
Melanoma Skin Cancer: A Comprehensive Review of Current Knowledge
Caraviello, C., Nazzaro, G., Tavoletti, G., Boggio, F. L., Denaro, N., Murgia, G., Passoni, E., Benzecry, V., & Marzano, A. V. (2025) · Cancers · doi:10.3390/cancers17172920 · Cited by 77
Molecular and genetic diversity in the metastatic process of melanoma
Harbst, K., Lauss, M., Cirenajwis, H., Winter, C., Howlin, J., Törngren, T., Kvist, A., Nodin, B., Olsson, E., Häkkinen, J., et al. (2014) · The Journal of Pathology · doi:10.1002/path.4318 · Cited by 77
Dissection of RAS downstream pathways in melanomagenesis: a role for Ral in transformation
Mishra, P. J., Ha, L., Rieker, J., Sviderskaya, E. V., Bennett, D. C., Oberst, M. D., Kelly, K., & Merlino, G. (2010) · Oncogene · doi:10.1038/onc.2009.521 · Cited by 68
Sclafani, F., Gullo, G., Sheahan, K. D., & Crown, J. P. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.11.003 · Cited by 76
Lachiewicz, A. M., Berwick, M., Wiggins, C. L., & Thomas, N. E. (2007) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5701028 · Cited by 76
Barbour, A. P., Tang, Y., Armour, N., Dutton‐Regester, K., Krause, L., Loffler, K. A., Lambie, D., Burmeister, B. H., Thomas, J. M., Smithers, B. M., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.06.009 · Cited by 76
KLF9-dependent ROS regulate melanoma progression in stage-specific manner
Bagati, A., Moparthy, S., Fink, E. E., Bianchi, A., Yun, D. H., Kolesnikova, M., Udartseva, O. O., Wolff, D. W., Roll, M. V., Lipchick, B. C., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0689-6 · Cited by 76
Dimitriou, F., Namikawa, K., Reijers, I. L. M., Buchbinder, E. I., Soon, J. A., Zaremba, A., Teterycz, P., Mooradian, M. J., Armstrong, E., Nakamura, Y., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.06.004 · Cited by 75
Váraljai, R., Zimmer, L., Al-Matary, Y. S., Kaptein, P., Albrecht, L. J., Shannan, B., Brase, J. C., Gusenleitner, D., Amaral, T. M. S., Wyss, N., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00610-2 · Cited by 76
Wu, J. M., Rosenbaum, E., Begum, S., & Westra, W. H. (2007) · American Journal of Dermatopathology · doi:10.1097/dad.0b013e3181584950 · Cited by 75
Barutello, G., Rolih, V., Arigoni, M., Tarone, L., Conti, L., Quaglino, E., Buracco, P., Cavallo, F., & Riccardo, F. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030799 · Cited by 76
Namikawa, K., Kiyohara, Y., Takenouchi, T., Uhara, H., Uchi, H., Yoshikawa, S., Takatsuka, S., Koga, H., Wada, N. A., Minami, H., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.09.025 · Cited by 75
Loss of microRNA-205 expression is associated with melanoma progression
Liu, S., Tetzlaff, M. T., Liu, A., Liegl-Atzwanger, B., Guo, J., & Xu, X. (2012) · Laboratory Investigation · doi:10.1038/labinvest.2012.62 · Cited by 74
Perng, P., Marcus, C. V., & Subramaniam, R. M. (2015) · American Journal of Roentgenology · doi:10.2214/ajr.14.13575 · Cited by 74
Acral lentiginous melanoma presents distinct clinical profile with high cancer susceptibility
Nagore, E., Pereda, C., Estrada, R. B., Requena, C., & Guillén, C. (2008) · Cancer Causes & Control · doi:10.1007/s10552-008-9221-y · Cited by 74
Hilke, F. J., Sinnberg, T. W., Gschwind, A., Niessner, H., Demidov, G. M., Amaral, T. M. S., Ossowski, S., Bonzheim, I., Röcken, M., Rieß, O., et al. (2020) · Cancers · doi:10.3390/cancers12092359 · Cited by 73
Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma
Larkin, J., & Fisher (2012) · Cancer Management and Research · doi:10.2147/cmar.s25284 · Cited by 76
the 11q13‐q14 amplicon: Clinicopathological correlations and potential drivers
Wilkerson, P. M., & Reis-Filho, J. S. (2012) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22037 · Cited by 73
High Frequency of p16 Promoter Methylation in NRAS-Mutated Cutaneous Melanoma
Jonsson, A., Tuominen, R., Grafström, E., Hansson, J., & Egyházi, S. (2010) · Journal of Investigative Dermatology · doi:10.1038/jid.2010.216 · Cited by 73
The chromatin remodelling factor BRG1 is a novel binding partner of the tumor suppressor p16INK4a
Becker, T. M., Haferkamp, S., Dijkstra, M. K., Scurr, L. L., Frausto, M., Diefenbach, E., Scolyer, R. A., Reisman, D. N., Mann, G. J., Kefford, R. F., et al. (2009) · Molecular Cancer · doi:10.1186/1476-4598-8-4 · Cited by 63
KIT amplification and gene mutations in acral/mucosal melanoma in Korea
Yun, J., Lee, J., Jang, J., Lee, E. J., Jang, K. T., Kim, J. H., & Kim, K. (2011) · Apmis · doi:10.1111/j.1600-0463.2011.02737.x · Cited by 72
Gerami, P., Pouryazdanparast, P., Vemula, S. S., & Bastian, B. C. (2010) · American Journal of Dermatopathology · doi:10.1097/dad.0b013e3181b96db7 · Cited by 72
Self-citationGenetics and genomics of melanoma
Ghosh, P., & Chin, L. (2009) · Expert Review of Dermatology · doi:10.1586/edm.09.2 · Cited by 74
Sunlight ultraviolet irradiation and BRAF V600 mutagenesis in human melanoma
Besaratinia, A., & Pfeifer, G. P. (2008) · Human Mutation · doi:10.1002/humu.20802 · Cited by 57
Cell Cycle Regulation and Melanoma
Xu, W., & McArthur, G. A. (2016) · Current Oncology Reports · doi:10.1007/s11912-016-0524-y · Cited by 73
Melanoma: Where we are and where we go
Mohammadpour, A., Derakhshan, M., Darabi, H., Hedayat, P., & Momeni, M. R. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27286 · Cited by 72
Hendricks, W. P. D., Zismann, V., Sivaprakasam, K., Legendre, C., Poorman, K. A., Tembe, W., Perdigones, N., Kiefer, J., Liang, W. S., DeLuca, V. J., et al. (2018) · PLoS Genetics · doi:10.1371/journal.pgen.1007589 · Cited by 73
A Review of Novel Therapies for Melanoma
Karimkhani, C., Gonzalez, R. C., & Dellavalle, R. P. (2014) · American Journal of Clinical Dermatology · doi:10.1007/s40257-014-0083-7 · Cited by 71
Hampering Immune Suppressors: Therapeutic Targeting of Myeloid-Derived Suppressor Cells in Cancer
Albeituni, S., Ding, C., & Yan, J. (2013) · The Cancer Journal · doi:10.1097/ppo.0000000000000006 · Cited by 71
Hedgehog signaling in skin cancers
Li, C., Chi, S., & Xie, J. (2011) · Cellular Signalling · doi:10.1016/j.cellsig.2011.03.002 · Cited by 72
Rajkumar, S., & Watson, I. R. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.195 · Cited by 57
The Current State of Molecular Testing in the BRAF-Mutated Melanoma Landscape
Vanni, I., Tanda, E. T., Spagnolo, F., Andreotti, V., Bruno, W., & Ghiorzo, P. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00113 · Cited by 72
Targeted Therapy Resistance Mechanisms and Therapeutic Implications in Melanoma
Chen, G., & Davies, M. A. (2014) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2014.03.001 · Cited by 70
Ungual melanoma - controversies in diagnosis and treatment
Haneke, E. (2012) · Dermatologic Therapy · doi:10.1111/j.1529-8019.2012.01515.x · Cited by 70
B-Raf mutation: A key player in molecular biology of cancer
Rahman, M. A., Salajegheh, A., Smith, R. A., & Lam, A. K.-Y. (2013) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2013.10.005 · Cited by 71
miR-124 inhibits cell proliferation in breast cancer through downregulation of CDK4
Feng, T., Xu, D., Tu, C., Li, W., Ning, Y., Ding, J., Wang, S., Yuan, L., Xu, N., Qian, K., et al. (2015) · Tumor Biology · doi:10.1007/s13277-015-3275-8 · Cited by 70
Devji, T., Levine, O. H., Neupane, B., Beyene, J., & Xie, F. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.4877 · Cited by 70
Melanoma immunology: past, present and future
Parmiani, G., Castelli, C., Santinami, M., & Rivoltini, L. (2007) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32801497d7 · Cited by 70
Tumor Immunotherapy in Melanoma: Strategies for Overcoming Mechanisms of Resistance and Escape
Zigler, M., Villares, G. J., Lev, D. C., Melnikova, V. O., & Bar‐Eli, M. (2008) · American Journal of Clinical Dermatology · doi:10.2165/00128071-200809050-00004 · Cited by 70
Melanoma pathology: new approaches and classification*
Yeh, I., & Bastian, B. C. (2021) · British Journal of Dermatology · doi:10.1111/bjd.20427 · Cited by 70
Self-citationMelanomas of unknown primary have a mutation profile consistent with cutaneous sun‐exposed melanoma
Dutton‐Regester, K., Kakavand, H., Aoude, L. G., Stark, M. S., Gartside, M. G., Johansson, P. A., O’Connor, L., Lanagan, C., Tembe, V., Pupo, G. M., et al. (2013) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12153 · Cited by 69
Management of Vulvar and Vaginal Melanomas: Current and Future Strategies
Leitão, M. M. (2014) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2014.34.e277 · Cited by 69
Spitz Nevi, Atypical Spitzoid Neoplasms, and Spitzoid Melanoma
Zedek, D. C., & McCalmont, T. H. (2011) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2011.03.008 · Cited by 69
Ragnarsson-Olding, B. K., Nilsson, P. J., Olding, L. B., & Nilsson, B. R. (2009) · Acta Oncologica · doi:10.1080/02841860802120861 · Cited by 69
Liu, F., Bessonova, L., Taylor, T. H., Ziogas, A., Meyskens, F. L., & Anton‐Culver, H. (2012) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12035 · Cited by 69
Melanoma: Clinical Features and Genomic Insights
Hawryluk, E. B., & Tsao, H. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a015388 · Cited by 72
A Tumor Suppressor Function for the Lipid Phosphatase INPP4B in Melanocytic Neoplasms
Pérez‐Lorenzo, R., Gill, K. Z., Shen, C., Zhao, F., Zheng, B., Schulze, H.-J., Silvers, D. N., Brunner, G., & Horst, B. A. J. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2013.511 · Cited by 68
Conjunctival Melanoma: Current Treatments and Future Options
Grimes, J. M., Shah, N. V., Samie, F. H., Carvajal, R. D., & Marr, B. P. (2020) · American Journal of Clinical Dermatology · doi:10.1007/s40257-019-00500-3 · Cited by 68
Packer, L., Pavey, S., Parker, A., Stark, M., Johansson, P., Clarke, B., Pollock, P., Ringner, M., & Hayward, N. (2006) · Carcinogenesis · doi:10.1093/carcin/bgl016 · Cited by 67
Perier‐Muzet, M., Thomas, L., Poulalhon, N., Debarbieux, S., Bringuier, P., Duru, G., Depaepe, L., Balme, B., & Dalle, S. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2013.462 · Cited by 67
Flaherty, K. T. (2012) · Annual Review of Medicine · doi:10.1146/annurev-med-050410-105655 · Cited by 64
RAF265 Inhibits the Growth of Advanced Human Melanoma Tumors
Su, Y., Vilgelm, A. E., Kelley, M. C., Hawkins, O. E., Liu, Y., Boyd, K. L., Kantrow, S., Splittgerber, R. C., Short, S. P., Sobolik, T., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1122 · Cited by 62
Biology, Therapy and Implications of Tumor Exosomes in the Progression of Melanoma
Isola, A. L., Eddy, K., & Chen, S. (2016) · Cancers · doi:10.3390/cancers8120110 · Cited by 68
The functional property of royal jelly 10-hydroxy-2-decenoic acid as a melanogenesis inhibitor
Peng, C., Sun, H.-T., Lin, I.-P., Kuo, P., & Li, J. (2017) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-017-1888-8 · Cited by 68
Vallacchi, V., Daniotti, M., Ratti, F., Stasi, D. D., Deho, P., Filippo, A. D., Tragni, G., Balsari, A., Carbone, A., Rivoltini, L., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2103 · Cited by 67
Haluska, F. G., Pemberton, T., Ibrahim, N., & Kalinsky, K. M. (2007) · Seminars in Oncology · doi:10.1053/j.seminoncol.2007.09.011 · Cited by 67
Recent developments in the medical and surgical treatment of melanoma
Saranga‐Perry, V., Ambe, C. M., Zager, J. S., & Kudchadkar, R. R. (2014) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21224 · Cited by 66
Resistance patterns with tyrosine kinase inhibitors in melanoma: new insights
Dummer, R., & Flaherty, K. T. (2012) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32834fca92 · Cited by 66
DAUD, A. I., Gill, J., Kamra, S., Chen, L., & Ahuja, A. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0369-8 · Cited by 66
Najem, A., Krayem, M., Salès, F., Hussein, N., Badran, B. M., Robert, C., Awada, A. H., Journé, F., & Ghanem, G. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.06.033 · Cited by 66
Kamino, H. (2009) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2008.09.013 · Cited by 66
Lelliott, E. J., McArthur, G. A., Oliaro, J., & Sheppard, K. E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.661737 · Cited by 65
“The p16 INK4a / CyclinD-CDK4/6/RB axis is dysregulated in numerous cancers, including around 90% of melanomas (49, 50).”
BackgroundMelanoma: A model for testing new agents in combination therapies
Ascierto, P. A., STREICHER, H. Z., & Sznol, M. (2010) · Journal of Translational Medicine · doi:10.1186/1479-5876-8-38 · Cited by 65
Metadata
- Authors
- Curtin, J. A., Fridlyand, J., Kageshita, T., Patel, H. N., Busam, K. J., Kutzner, H., Cho, K.-H., Aiba, S., Bröcker, E.-B., LeBoit, P. E., Pinkel, D., & Bastian, B. C.
- Affiliations
- University of California, San Francisco (US)
- Kumamoto University Hospital (JP)
- Memorial Sloan Kettering Cancer Center (US)
- Dermatopathologie Friedrichshafen (DE)
- Seoul National University (KR)
- Tohoku University (JP)
- University of Würzburg (DE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-11-17
- Volume
- 353
- Issue
- 20
- Pages
- 2135-2147
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1989121777
- Cited by
- 2,747
- References
- 38
- Citations by year
- 2026: 54 · 2025: 69 · 2024: 87 · 2023: 91 · 2022: 85 · 2021: 125 · 2020: 165 · 2019: 133 · 2018: 130 · 2017: 164 · 2016: 157 · 2015: 170 · 2014: 197 · 2013: 218 · 2012: 202
- FWCI
- 33.63
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion)
- Funders
- National Cancer Institute (R01CA094963, R33 CA95300, R33CA095300)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- melanoma, UV exposure, acral melanoma, mucosal melanoma, BRAF mutation, NRAS mutation, copy number alterations, CDK4, CCND1, oncogenes, tumor genetic heterogeneity, skin cancer
- MeSH terms
- Adult, Aged, Aged, 80 and over, DNA, Neoplasm, Environmental Exposure, Female, Humans, Male, Melanoma, Middle Aged, Mutation, Nucleic Acid Hybridization, Genes, ras, Risk Factors, Skin Neoplasms, Ultraviolet Rays, Signal Transduction, Genome, Human, Phosphatidylinositol 3-Kinases, Cyclin D1, Mitogen-Activated Protein Kinases, Proto-Oncogene Proteins B-raf, PTEN Phosphohydrolase, Cyclin-Dependent Kinase 4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.